Table 2.

Concentrations of rifapentine and its main metabolite (25-desacetyl rifapentine) in plasma

BAL group and drugaConcn in plasma
At 2 h postdosingAt time of BALAt 20–24 h postdosing
4 h
 RFP4.5 ± 1.7b13.3 ± 9.24.1 ± 2.6
 25-dR0.0 ± 0.0c4.9 ± 3.54.8 ± 3.6
5 h
 RFP13.2 ± 3.626.2 ± 6.1d7.6 ± 1.1
 25-dR1.6 ± 0.4c8.2 ± 2.66.8 ± 2.6
7 h
 RFP13.9 ± 3.6b14.9 ± 4.96.7 ± 1.7
 25-dR1.5 ± 0.76.3 ± 2.15.0 ± 2.6
12 h
 RFP9.7 ± 5.515.5 ± 4.410.7 ± 4.0
 25-dR0.5 ± 0.57.6 ± 2.27.6 ± 3.1
24 h
 RFP9.1 ± 4.78.2 ± 1.9d7.9 ± 2.9
 25-dR0.6 ± 0.77.7 ± 4.75.8 ± 4.3
48 h
 RFP9.7 ± 2.23.4 ± 3.2d9.8 ± 7.4
 25-dR1.1 ± 0.55.1 ± 4.77.3 ± 5.3
  • a RFP, rifapentine; 25-dR, 25-desacetyl rifapentine.

  • b For 7-h rifapentine group versus 4-h rifapentine group, P < 0.05.

  • c For 5-h 25-desacetyl rifapentine group versus 4-h 25-desacetyl rifapentine group, P < 0.05.

  • d For 5-h rifapentine group versus 24-h and 48-h rifapentine groups, P < 0.05.